CD8A and neoplasm: Similar to the CRISPR-targeted Usp22 inhibition, USP22i-S02 treatment synergized with anti–PD-1 resulted in a nearly complete inhibition of both RM1 and MC38 tumor growth with increased CD8 antitumor immunity (Supplemental Figure 6).